Department of Pharmacology & Therapeutics, McGill University, Bellini Life Science Complex, Room 167, 3649 Promenade Sir-William-Osler, Montreal, QC, H3G 0B1, Canada.
Eur J Neurosci. 2014 Sep;40(5):2766-76. doi: 10.1111/ejn.12638. Epub 2014 Jun 13.
CX 546, an allosteric positive modulator of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-type ionotropic glutamate receptors (AMPARs), belongs to a drug class called ampakines. These compounds have been shown to enhance long-term potentiation (LTP), a cellular model of learning and memory, and improve animal learning task performance, and have augmented cognition in neurodegenerative patients. However, the chronic effect of CX546 on synaptic structures has not been examined. The structure and integrity of dendritic spines are thought to play a role in learning and memory, and their abnormalities have been implicated in cognitive disorders. In addition, their structural plasticity has been shown to be important for cognitive function, such that dendritic spine remodeling has been proposed as the morphological correlate for LTP. Here, we tested the effect of CX546 on dendritic spine remodeling following long-term treatment. We found that, with prolonged CX546 treatment, organotypic hippocampal slice cultures showed a significant reduction in CA3-CA1 excitatory synapse and spine density. Electrophysiological approaches revealed that the CA3-CA1 circuitry compensates for this synapse loss by increasing synaptic efficacy through enhancement of presynaptic release probability. CX546-treated slices showed prolonged and enhanced potentiation upon LTP induction. Furthermore, structural plasticity, namely spine head enlargement, was also more pronounced after CX546 treatment. Our results suggest a concordance of functional and structural changes that is enhanced with prolonged CX546 exposure. Thus, the improved cognitive ability of patients receiving ampakine treatment may result from the priming of synapses through increases in the structural plasticity and functional reliability of hippocampal synapses.
CX546 是一种 α-氨基-3-羟基-5-甲基-4-异恶唑丙酸型离子型谷氨酸受体(AMPAR)的别构正变构调节剂,属于一类称为ampakines 的药物。这些化合物已被证明可增强长时程增强(LTP),这是学习和记忆的细胞模型,并改善动物学习任务的表现,并在神经退行性疾病患者中增强认知。然而,CX546 对突触结构的慢性影响尚未被检测到。树突棘的结构和完整性被认为在学习和记忆中起作用,其异常与认知障碍有关。此外,它们的结构可塑性对于认知功能很重要,例如,树突棘重塑已被提出作为 LTP 的形态学相关物。在这里,我们测试了 CX546 在长期治疗后对树突棘重塑的影响。我们发现,随着 CX546 治疗时间的延长,器官型海马切片培养物显示 CA3-CA1 兴奋性突触和棘突密度显著降低。电生理方法表明,CA3-CA1 电路通过增强突触前释放概率来增加突触效能,从而补偿这种突触损失。CX546 处理的切片在 LTP 诱导时显示出延长和增强的增强。此外,结构可塑性,即棘突头的增大,在 CX546 处理后也更为明显。我们的结果表明,功能和结构变化的一致性随着 CX546 暴露时间的延长而增强。因此,接受 ampakine 治疗的患者认知能力的提高可能是由于通过增加海马突触的结构可塑性和功能可靠性来启动突触。